ENDRA Life Sciences Business Summary

ENDRA Life Sciences Inc. (NDRA) operates as a medical technology pioneer specializing in non-invasive diagnostic tools, primarily generating revenue through a subscription-based Software-as-a-Service (SaaS) model for its proprietary Thermo Acoustic Enhanced UltraSound (TAEUS) platform. The company’s business is bifurcated into two strategic segments: its core Medical Imaging division, which targets pharmaceutical companies, CROs, and metabolic clinics for the quantification of liver fat in Steatotic Liver Disease (SLD) and MASH trials, and its Digital Asset Treasury (DAT) division. Launched in late 2025, the DAT segment manages a high-conviction portfolio of decentralized finance (DeFi) assets, such as HYPE tokens, utilizing staking and yield-enhancement strategies to provide non-dilutive capital for clinical operations. ENDRA competes directly with Echosens (FibroScan), SonicIncytes (Velacur), and Perspectum, positioning itself as a high-accuracy, point-of-care alternative that delivers MRI-PDFF-level precision at approximately 1/50th the cost, specifically addressing diagnostic gaps in high-BMI patient populations. The leadership team is anchored by CEO Alexander Tokman and CTO/Founder Michael Thornton, both of whom possess deep institutional pedigree from GE Healthcare. Tokman previously led GE’s Global Molecular Imaging and Radiopharmacy business and served as CEO of Microvision, while Thornton founded Enhanced Vision Systems (acquired by GE) and held senior product management roles at GE Healthcare. The executive suite is further strengthened by CFO Richard Jacroux, an Ernst & Young veteran, and Ziad Rouag, Head of Clinical and Regulatory Affairs, who brings extensive experience from Biomodex and Juul Labs. The company’s strategic direction is supported by a notable Board of Directors including Michael Harsh, the former CTO of GE Healthcare, and is bolstered by a financial partnership with Arca Investment Management, which oversees the firm’s digital asset strategy.